BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jan 10, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Aclidinium bromide and formoterol: Phase IIb data

Two dose-ranging Phase IIb trials in patients with stable moderate to severe COPD showed that a twice-daily fixed dose combination of aclidinium bromide and formoterol met the primary endpoint of significantly improving FEV1 at 12 hours vs. placebo (p<0.001). The...

Read the full 177 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >